Search clinical trials for: Selective Internal Radiation Therapy

Total 60708 results

Chengdu New Radiomedicine Technology Co. LTD.

Recruiting

Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Oslo University Hospital

Recruiting

HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (TOMCAT)

Intrahepatic Cholangiocarcinoma | Chemotherapy Effect

Norway
Chengdu New Radiomedicine Technology Co. LTD.

Not yet recruiting

Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC)

Unresectable Pancreatic Cancer

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

SIRT for Potentially Resectable HCC

Hepatocellular Carcinoma

China
Center Eugene Marquis

Recruiting

Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2) (Lip-Re2)

Hepatocellular Carcinoma Non-resectable

France
Zhongda Hospital

Recruiting

Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases (NRT-uCRLM)

Unresectable Colorectal Liver Metastases

China
Emory University
National Cancer Institute (NCI)

Recruiting

BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Sirtex Medical
Bright Research Partners

Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients (DOORwaY90)

Unresectable Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Federation Francophone de Cancerologie Digestive

Recruiting

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI)

Metastatic Colorectal Cancer | MSS | pMMR | Immune Checkpoint Inhibitor | Internal Radiotherapy

France
University of Michigan Rogel Cancer Center
Department of Health and Human Services; National Institute for Biomedical...

Recruiting

Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Liver Malignancy

United States
Aarhus University Hospital

Recruiting

Selective Internal Radiation Therapy With 90Y Resin Micropheres for Refractory Colorectal Cancer Liver Metastases (SIRT)

Liver Metastasis Colon Cancer

Denmark
Imperial College London
Biocompatibles UK Ltd, a BT International group company

Recruiting

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets (ArTisaN)

Neuroendocrine Tumors | Liver Metastases

United Kingdom
Center Eugene Marquis

Suspended

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer (SIROCHO)

Resectable Intrahepatic Cholangiocarcinoma

France
National Cancer Centre, Singapore

Active, not recruiting

Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

HepatoCellular Carcinoma

Singapore
Terumo Europe N.V.

Completed

Holmium-166 Retrospective Collection of Real-World Data (RECORD)

Hepatocellular Carcinoma | Metastatic Cancer

Netherlands, Germany, Switzerland, Belgium, Spain, Portugal, Italy
Terumo Europe N.V.

Terminated

QuiremSpheres Observational Study (Hope166)

Liver, Cancer of, Non-Resectable

Netherlands, Germany
Leiden University Medical Center
Medtronic; ZonMw: The Netherlands Organisation for Health Research and Development and other collaborators

Completed

Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study (HORA EST HCC)

HCC | Early Stage HCC

Netherlands
Sirtex Medical

Terminated

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular | Hepatoma

United States
University of Colorado, Denver
AstraZeneca

Withdrawn

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Colorectal Cancer
University of California, San Francisco

Terminated

Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Roger Williams Medical Center
Sirtex Medical

Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases (HITM-SIR)

Liver Metastases

United States
Nicholas Fidelman, MD

Completed

Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases

Melanoma | Breast Cancer | Colorectal Neoplasms | Neuroendocrine Tumors | Cholangiocarcinoma
Singapore General Hospital
National Cancer Centre, Singapore; National Medical Research Council (NMRC)... and other collaborators

Unknown

Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB)

Hepatocellular Carcinoma

Taiwan, Korea, Republic of, Malaysia, New Zealand, Philippines, Singapore, China, Thailand, Brunei Darussalam, Indonesia, Mongolia, Myanmar
Masonic Cancer Center, University of Minnesota

Terminated

Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ

Breast Cancer

United States
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Unknown

REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)

Hepatocellular Carcinoma

Taiwan
Johannes Gutenberg University Mainz

Completed

Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).

Hepatocellular Carcinoma
Fox Chase Cancer Center
Sirtex Medical

Completed

Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer

Metastatic Liver Cancer

United States
Memorial Sloan Kettering Cancer Center
Sirtex Medical

Completed

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

Rectal Cancer | Colon Cancer

United States
Goshen Health System

Unknown

Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery

Pancreatic Cancer | Metastatic Cancer

United States
University of Kansas Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8

United States
University of Maryland, Baltimore

Recruiting

Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) (SAVAL)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell Carcinoma

United States
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma (HOLMBRAVE)

Hepatocellular Carcinoma

France
UNC Lineberger Comprehensive Cancer Center

Recruiting

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN)

Quality of Life | Breast Cancer

United States
National Cancer Institute (NCI)

Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Australia, Canada, New Zealand
Kafrelsheikh University
Ministry of Health, Saudi Arabia; Foshan University Laboratory of Emerging... and other collaborators

Not yet recruiting

Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.

Post COVID-19 Anosmia (Loss of Smell)

China, Egypt, Saudi Arabia
NRG Oncology
National Cancer Institute (NCI)

Recruiting

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (DEBRA)

Stage I Breast Cancer

United States, Canada, Hong Kong
Azienda Ospedaliero-Universitaria Careggi
University of Florence

Recruiting

ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years Early Stage Breast Cancer (EUROPA)

Breast Cancer

Italy
Northwestern University
National Cancer Institute (NCI)

Recruiting

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

Cancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In Situ

United States
Yonsei University

Recruiting

Standard of Care Therapy With Involved Field Radiation Therapy for Selective Recurrent Ovarian Cancer

Recurrent Ovarian Cancer

Korea, Republic of
University of Utah

Recruiting

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (SAVE)

Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Serous Adenocarcinoma | Uterine Corpus Sarcoma | Uterine Corpus Carcinosarcoma | Stage IA Uterine Corpus Cancer | Stage IB Uterine Corpus Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Endometrial Endometrioid Adenocarcinoma | Stage I Uterine Corpus Cancer AJCC v8 | Stage II Uterine Corpus Cancer AJCC v8

United States, Puerto Rico
University of Maryland, Baltimore

Active, not recruiting

Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) (SAVER)

Head and Neck Cancer | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Cancer

United States
Bayer

Active, not recruiting

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF)

Heart Failure

United States, Spain, Denmark, Korea, Republic of, Taiwan, Australia, Hong Kong, Russian Federation, Israel, Canada, Malaysia, United Kingdom, Latvia, Netherlands, Japan, Brazil, China, Lithuania, Poland, Turkey, Italy, Austria, Bul... and more
Janssen Research & Development, LLC

Active, not recruiting

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Crohn's Disease

United States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, Turkey, China, United Kingdom and more
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of

Search clinical trials for: Selective Internal Radiation Therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations